2,4,6-Trimethoxyphenethylamine
2,4,6-Trimethoxyphenethylamine, also known as TMPEA-6, 2C-TMA-6, or ψ-2C-O, is a drug of the phenethylamine and Ψ-PEA families. It is a positional isomer of mescaline and 2C-O as well as the α-desmethyl analogue of 2,4,6-trimethoxyamphetamine. The drug has been encountered online as a novel designer drug.
According to Daniel Trachsel in 2012, who cited personal communication with P. Rausch in 2009, the drug has been reported to be inactive in humans at a dose of up to 300mg or more. This is similar to the case of 2C-O, but is in contrast to mescaline as well as TMA-6.
Pharmacology
Pharmacodynamics
Unlike mescaline, but similarly to 2C-O, 2,4,6-TMPEA does not appear to be a substrate for amine oxidase.
Chemistry
Derivatives
A variety of derivatives of 2,4,6-TMPEA are known.
History
2,4,6-TMPEA was first described in the scientific literature by 1954. Alexander Shulgin mentioned 2,4,6-TMPEA in his 1991 book PiHKAL and stated that its activity in humans was unknown at the time. The compound was encountered as a novel designer drug in Russia in 2023.
Canada
2,4,6-TMPEA is a controlled substance in Canada under phenethylamine blanket-ban language.